**Acknowledgements**

We wish to express sincere thanks to Professor Dr. Edwin L. Cooper, *Distinguished Professor, at* Collaborative Centers for Integrative Medicine, University of California, Los Angeles, for critically editing this manuscript. We wish to dedicate this chapter to Professor Edwin L Cooper. We also wish to thank Professor Mark Terasaki and Terasaki Family Foundation for providing financial support to carry out the research reported in this chapter at Terasaki Foundation Laboratory (TFL), Santa Monica, CA. We wish to thank the following research scientists at TFL, Drs. Dong Zhu, Toshiyuki Sasaki, Vadim Jucaud, Mr. Tho Pham, Mr. Satoru Kawakita, Mr. Curtis Y. Maehara, and Mrs. Judy Hopfield were directly involved in the experiments reported in this chapter.

A patent was filed based on our research on monospecific anti-HLA-E mAb TFL-033 and a U. S. Patent No 10,656,158 B2 was issued on May 19, 2020, to Dr. Mepur H. Ravindranath & Late Professor Paul Ichiro Terasaki. Hybridoma of TFL-033 is deposited with ATCC Patent Depository (ID: PTA-125908) at Manassas, Virginia 20110, USA.
